tbuckley/cabot-search huggingface dataset:
Abstract 4223: Possible usefulness of spirulina platensis for supression of some cases of hepatocellular carcinoma, multiple case study
Authors: Raghda A. Hafez, Osama M. Basha, Yassin M. El Ayoty, Refaat A. Sadeq, Haitham Dawood
Journal: Cancer Research (2011)

Abstract Backgrownd and study aims; One of the most frequent carcinoma through the world is hepato cellular carcinoma (HCC). It is rapidly fatal with a life expectancy of about 6 months from the time of diagnosis. The disease is more prevalent in parts of Africa and Asia with a strong etiological association with viral hepatitis, haemochromatosis, known carcinogen and toxins. There are many therapeutic options for HCC including; surgical operations, chemotherapy, radiofrequency, immune therapy and gene therapy. The use of natural products as drugs is gaining increasing interest especially due to reduced side effects, if any. In this study, we followed up hepatic patients with HCC, taking hot water extract of sterilized blue green alga, spirulina platenesis. Seven volunteers with cirrhotic liver resulting from chronic viral C hepatitis that had developed HCC were followed up in this work. All available investigations including laboratory and imaging facilities were done before starting the study and repeated monthly for follow up during the study.Results; After 10-15 months, patients are still alive, showing an improvement in the general condition with an obvious regression of the tumor size as well as, better liver functions. Also no obvious side effects were detected during the study.Conclusion; These observations may direct our attentions towards the possibility that the “water extract of sterilized blue green algae; spirulina platenesis” may be of therapeutic value in treatment and/or amelioration of symptoms of hepato cellular carcinoma especially in cirrhotic patients. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 4223. doi:10.1158/1538-7445.AM2011-4223
The Education of the Student in Practical Midwifery
Authors: R. R. Rentoul
Journal: BMJ (1895)

IAT the education of the student in practical midwifery is sadly neglected, when we consider the attention which he is compelled to give medicine and surgery, few practical persons will dispute.The fact, however, that in his future practice this student will be brought into much closer relation with midwifery and diseases of infants, should induce the medical authorities to look much more closely into this question; one which so intimately bears upon the lives and health of women and infants.
Preserved response of mitochondrial function to short-term endurance training in skeletal muscle of heart transplant recipients
Authors: Joffrey Zoll, Benoit N’Guessan, Florence Ribera, Eliane Lampert, Dominique Fortin, Vladimir Veksler, Xavier Bigard, Bernard Geny, Jean Lonsdorfer, Renée Ventura-Clapier, Bertrand Mettauer
Journal: Journal of the American College of Cardiology (2003)
Misleading Statement in Trial on False-Positive Results in Lung Cancer Screening
Authors: H. Nancy Sokol
Journal: Annals of Internal Medicine (2010)

Letters3 August 2010Misleading Statement in Trial on False-Positive Results in Lung Cancer ScreeningH. Nancy Sokol, MDH. Nancy Sokol, MDFrom Harvard Medical School, Boston, MA 02115.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-153-3-201008030-00019 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:The introduction to the article by Croswell and colleagues (1) on false-positive results in lung cancer screening acknowledges the increasing public attention and political advocacy for lung cancer screening in recent years. It then says that “surveys of U.S. community physicians … found that two thirds of family practitioners, internists, and gynecologists and 82% of general surgeons recommended chest radiography for lung cancer screening every 1 to 2 years” (1). I believe this statement is misleading.The reference cited is a 1994 study (2) in which physicians were surveyed by telephone or mail between October 1989 and ...References1. Croswell JM, Baker SG, Marcus PM, Clapp JD, Kramer BS. Cumulative incidence of false-positive test results in lung cancer screening: a randomized trial. Ann Intern Med. 2010;152:505-12, W176-80. [PMID: 20404381] LinkGoogle Scholar2. Czaja R, McFall SL, Warnecke RB, Ford L, Kaluzny AD. Preferences of community physicians for cancer screening guidelines. Ann Intern Med. 1994;120:602-8. [PMID: 8117000] LinkGoogle Scholar Author, Article, and Disclosure InformationAffiliations: From Harvard Medical School, Boston, MA 02115.Disclosures: None disclosed. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoPreferences of Community Physicians for Cancer Screening Guidelines Ronald Czaja , Stephanie L. McFall , Richard B. Warnecke , Leslie Ford , and Arnold D. Kaluzny Cumulative Incidence of False-Positive Test Results in Lung Cancer Screening Jennifer M. Croswell , Stuart G. Baker , Pamela M. Marcus , Jonathan D. Clapp , and Barnett S. Kramer Metrics 3 August 2010Volume 153, Issue 3Page: 210KeywordsCervical cancerColonComputed axial tomographyConflicts of interestDiagnostic radiologyLung and intrathoracic tumorsLung cancer screeningSurgeonsThoraxTreatment guidelines ePublished: 3 August 2010 Issue Published: 3 August 2010 CopyrightCopyright © 2010 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...
Human Erythropoietin Gene Delivery Using an Arginine-grafted Bioreducible Polymer System
Authors: Youngsook Lee, Hye Yeong Nam, Jaesung Kim, Minhyung Lee, James W Yockman, Sug Kyun Shin, Sung Wan Kim
Journal: Molecular Therapy (2012)

Erythropoiesis-stimulating agents are widely used to treat anemia for chronic kidney disease (CKD) and cancer, however, several clinical limitations impede their effectiveness. Nonviral gene therapy systems are a novel solution to these problems as they provide stable and low immunogenic protein expression levels. Here, we show the application of an arginine-grafted bioreducible poly(disulfide amine) (ABP) polymer gene delivery system as a platform for in vivo transfer of human erythropoietin plasmid DNA (phEPO) to produce long-term, therapeutic erythropoiesis. A single systemic injection of phEPO/ABP polyplex led to higher hematocrit levels over a 60-day period accompanied with reticulocytosis and high hEPO protein expression. In addition, we found that the distinct temporal and spatial distribution of phEPO/ABP polyplexes contributed to increased erythropoietic effects compared to those of traditional EPO therapies. Overall, our study suggests that ABP polymer-based gene therapy provides a promising clinical strategy to reach effective therapeutic levels of hEPO gene. Erythropoiesis-stimulating agents are widely used to treat anemia for chronic kidney disease (CKD) and cancer, however, several clinical limitations impede their effectiveness. Nonviral gene therapy systems are a novel solution to these problems as they provide stable and low immunogenic protein expression levels. Here, we show the application of an arginine-grafted bioreducible poly(disulfide amine) (ABP) polymer gene delivery system as a platform for in vivo transfer of human erythropoietin plasmid DNA (phEPO) to produce long-term, therapeutic erythropoiesis. A single systemic injection of phEPO/ABP polyplex led to higher hematocrit levels over a 60-day period accompanied with reticulocytosis and high hEPO protein expression. In addition, we found that the distinct temporal and spatial distribution of phEPO/ABP polyplexes contributed to increased erythropoietic effects compared to those of traditional EPO therapies. Overall, our study suggests that ABP polymer-based gene therapy provides a promising clinical strategy to reach effective therapeutic levels of hEPO gene.
Decision about stopping hormone replacement therapy
Authors: H. Roberts
Journal: BMJ (2010)

A 54 year old woman was referred by her general practitioner to discuss her ongoing use of oral hormone replacement. She started this when she was 46 years old because of night sweats. At this time she was still menstruating and has continued to have regular periods while taking hormone replacement. Her general practitioner has advised her to stop using hormones, but she is keen to continue treatment because it has completely resolved her night sweats. She asked to be referred for a second opinion. On further discussion, she had other reasons for wishing to continue using hormone replacement. She had recently asked her general practitioner to send her for a bone mineral density scan, and she brought the result with her. The report said that she had osteoporosis (t score −2.5 at the femoral neck), which she felt was another good reason to continue with the treatment. Also, despite her general practitioner having spoken with her about the risks of ongoing hormone replacement use, she had read that because she started taking it when she was younger, continuing to take it might in fact lower her risk of heart attack. She had no relevant medical or family history and was taking no other drugs. Investigations for low bone mineral density including serum calcium, alkaline phosphatase, thyroid function, and renal function were normal. She was a non-smoker.
Velázquez' Dwarfs: A Profusion of Diagnoses-Reply
Authors: Rodrigo Dominguez
Journal: JAMA (1989)

In Reply. —  The subject of bone dysplasias is still not very well understood and consequently open to controversy; the untreated cretin usually presents with epiphyseal dysgenesis and metaphyseal and disaphyseal dysplastic changes secondary to delayed and abnormal skeletal maturation. The results are stunted height, coxa plana, bowed legs, increased lumbar kyphosis, and shortening at the base of the skull,1,2features that may resemble those of achondroplasia and some forms of mucopolysaccharidosis.El Nino de Vallecas, besides his dwarfed body, has the stunted look of an idiot, a feature absent in the normally intelligent achondroplastic.  Velazquez has several paintings of dwarfs at the Prado Museum in Madrid, Spain. The female dwarf displayed in his paintingLas Meninaswas Maria Barbola, a German lady-in-waiting for the princess and most probably an achondroplastic.
Feminist Group Plans "Economic Pressure Campaign" for Access To RU 486
Authors: S. Jenks
Journal: JNCI Journal of the National Cancer Institute (1992)

A grant for $10 million has boosted the efforts of the Feminist majority Foundation, a Boston activist group committed to bringing RU-486 into the US. The group is planning to research the corporate structure of Hoechst, A.G., the owner of Roussel-Uclaf, and that of its US subsidiary Hoechst Celanese Corporation of Somerville, NJ. Ultimate strategies may include a boycott of Hoechst products in the US, formation of a consortium of small pharmaceutical companies, or of a feminist pharmaceutical firm to research and develop RU-486 or other antiprogestins for the US. The Hoechst Company denies any connection to Roussel-Uclaf. Meanwhile, US researchers have organized in some states to encourage research on the drug, and a bill has been introduced to force the US Food and Drug Administration to lift its ban on importation. An opposition bill to ban importation of RU-486 for any purpose including research has also been introduced by right-to-life forces. New research is underway to test the antineoplastic effects of RU-486 on breast cancer in Canada, and on meningioma in California.
Esophageal Achalasia Probably Due to Gastric Carcinoma
Authors: MARVIN KOLODNY
Journal: Annals of Internal Medicine (1968)

A case of invasive gastric carcinoma mimicked idiopathic achalasia. Esophagoscopy, cineradiography, exfoliative cytology, manometry, and the methacholine (Mecholyl⌖) test were consistent with idiopathic achalasia. Only a high index of suspicion based on the short duration of symptoms and particularly the suggestion of a fundal mass in the upper gastrointestinal series led to the correct diagnosis. The demonstrated carcinomatous involvement of the esophageal ganglia probably produced the achalasia.
Increased Iodine Uptake in the Nabothian Cyst
Authors: Shuai Liu, Min Zhang, Yumin Qu, Yu Pan, Yifan Zhang
Journal: Clinical Nuclear Medicine (2013)

A 31-year-old female patient with papillary thyroid cancer, status post-total thyroidectomy and radioablation with (131)I underwent posttherapy whole-body scan with SPECT, which revealed increased iodine activity in the cervix. The subsequent ultrasound examination demonstrated that the site of elevated iodine activity was caused by cervical Nabothian cyst.
TUSC4 Functions as a Tumor Suppressor by Regulating BRCA1 Stability
Authors: Yang Peng, Hui Dai, Edward Wang, Curtis Chun-Jen Lin, Wei Mo, Guang Peng, Shiaw-Yih Lin
Journal: Cancer Research (2014)

Abstract BRCA1 expression is lost frequently in breast cancers in which it promotes malignant development. In the present study, we performed a global expression analysis of breast cancer cells in which the tumor-suppressor candidate gene TUSC4 was silenced to gain insights into its function. TUSC4 silencing affected genes involved in cell cycle and cell death, which have broad reaching influence on cancer development. Most importantly, we found a cluster pattern of gene-expression profiles in TUSC4-silenced cells that defined a homologous recombination (HR) repair defect signature. Mechanistic investigations indicated that TUSC4 protein could physically interact with the E3 ligase Herc2, which prevents BRCA1 degradation through the ubiquitination pathway. TUSC4 silencing enhanced BRCA1 polyubiquitination, leading to its degradation and a marked reduction in HR repair efficiency. Notably, ectopic expression of TUSC4 suppressed the proliferation, invasion, and colony formation of breast cancer cells in vitro and tumorigenesis in vivo. Furthermore, TUSC4 silencing was sufficient to transform normal mammary epithelial cells and to enhance sensitivity to PARP inhibitors. Our results provide a set of genetic and biologic proofs that TUSC4 functions as a bona fide tumor suppressor by regulating the protein stability and function of BRCA1 in breast cancer. Cancer Res; 75(2); 378–86. ©2014 AACR.
Alveolar and Dead Space Volume Measured by Oscillations of Inspired Oxygen in Awake Adults
Authors: E. M. WILLIAMS, R. M. HAMILTON, L. SUTTON, J. P. VIALE, C. E. W. HAHN
Journal: American Journal of Respiratory and Critical Care Medicine (1997)

Forced sinusoidal oscillations in the inspired concentration of a low-solubility inert gas can be used to measure airways dead space and alveolar volume. When inspired oxygen is oscillated about its mean value in the same way, the ratio between the amplitudes of the resulting end-expired and inspired oxygen oscillations is the same as that of an inert gas such as argon. Thus, oxygen forcing oscillations can be used to measure lung volume. In nine healthy spontaneously breathing adults, the FIO2 (mean FIO2 = 0.26, mean minute volume = 8.5 L/min) was forced to sinusoidally oscillate with an amplitude of +/- 0.04. The mean airways dead space measured using FIO2 oscillations with a forcing period of 3 min was 0.17 +/- 0.04 L, and the airways dead space measured by a single-breath C02 technique was no different at 0.19 +/- 0.03 L. An oxygen oscillation of the same period measured the mean end-expired alveolar volume at 3.1 +/- 0.7 L. Adding together the airways dead space and end-expired alveolar volume, obtained by the oxygen oscillation technique, provided a measure of FRC that at 3.3 +/- 0.7 L matched the FRC of 3.3 +/- 0.8 L measured by whole-body plethysmography. A third measure of FRC using a multiple-breath nitrogen washout technique gave a smaller volume of 3.00 +/- 0.85 L. The advantage of using FIO2 oscillations is that accurate FRC measurements can be made continuously, without interfering with the subject's natural breathing rhythm.
From the Office of the General Counsel. Physician participation in assisted suicide
Authors: D. Orentlicher
Journal: JAMA (1989)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Transplanted Infections: Donor-to-Host Transmission with the Allograft
Authors: Keith M. Gottesdiener
Journal: Annals of Internal Medicine (1989)

Purpose: To evaluate the transmission of infectious agents from organ donors to transplant recipients, and to assess risk factors for transmission, primarily in recipients of kidney, cornea, and heart allografts. Data Identification: Computerized literature searches of MEDLINE and PAPERCHASE through January 1988, extensive review of references from identified articles, and review of major clinical and transplantation journals through June 1988. Study Selection: All case reports and studies that reported a possible donor-to-recipient transmission of infection were selected and reviewed. Data Extraction: Each case report or patient series of donor-to-recipient transmission was judged as possible, probable, or proven depending on the completeness of donor and recipient information available and the likelihood of alternate causes of infection. Results of Data Synthesis: True donor-transmitted infection can occur with viruses including human immunodeficiency virus, cytomegalovirus, herpes simplex, EpsteinBarr, rabies, the virus causing Creutzfeldt-Jakob disease, and with hepatitis B virus. It can also occur with many common aerobic bacteria, although allograft-transmitted bacterial infection is more often caused by contamination during harvesting and processing. Fungi and yeast, as well as toxoplasmosis, have been transmitted less frequently, and there have been rare instances when mycobacterial infection, malaria, trypanosomiasis, and strongyloidiasis have been transplanted with the donor organ. Conclusions: Infection can be transmitted with a donor organ to the recipient, but contamination of the organ during processing and harvesting is commoner and may lead to severe infection in the recipient, especially if contamination is by one of a subset of more virulent organisms. True donortransmitted infection, although rare, can be reduced by careful donor screening, which should include clinical and epidemiologic assessment for evidence of infection, as well as judicious laboratory testing.
Letter: SI units.
Authors: J T Roberts
Journal: BMJ (1976)

The bleeding time (Ivy method) was, however, normal in all 23 patients studied.None of the patients in this small series was thrombocytopenic.It is unlikely that this acquired platelet funotion defect will be of clinical significance, but until further experience is gained with this agent it would seem advisable to measure the bleeding time and platelet count before major surgery in patients taking sodium valproate.
Microarray-based classification of a consecutive series of 121 childhood acute leukemias: prediction of leukemic and genetic subtype as well as of minimal residual disease status
Authors: A Andersson, C Ritz, D Lindgren, P Edén, C Lassen, J Heldrup, T Olofsson, J Råde, M Fontes, A Porwit-MacDonald, M Behrendtz, M Höglund, B Johansson, T Fioretos
Journal: Leukemia (2007)
Multicentric warfarin-induced skin necrosis complicating heparin-induced thrombocytopenia
Authors: Theodore E. Warkentin, William M. Sikov, David P. Lillicrap
Journal: American Journal of Hematology (1999)

Two patients developed catastrophic multicentric skin necrosis while receiving warfarin to treat venous thromboembolism complicated by immune-mediated heparin-induced thrombocytopenia (HIT). Patient 1 developed skin necrosis involving the breasts, thighs, and face, as well as venous limb gangrene and bilateral hemorrhagic necrosis of the adrenal glands, resulting in death. The second patient developed bilateral mammary necrosis necessitating mastectomies, as well as skin necrosis involving the thigh. Neither patient had an identifiable hypercoagulable syndrome, other than HIT. HIT may represent a risk factor for the development of multicentric warfarin-induced skin necrosis (WISN).
Oral Contraceptives and Stroke
Authors: Martin P. Vessey
Journal: New England Journal of Medicine (1973)

Epidemiologic studies carried out in the United Kingdom and in the United States have left little doubt that oral contraceptives are a cause of deep vein thrombosis and pulmonary embolism. The evidence linking oral contraceptives with an increased risk of cerebral thrombosis, however, is less certain. The study by the Collaborative Group for the Study of Stroke in Young Women, (p. 871) provides important new information about this association.During a two-year period from 1969- 71, neurologists from 12 university hospitals identified 598 nonpregnant women, 15 to 44 years of age, suffering from a stroke unrelated to trauma. These patients . . .
A Formula for Calculating the Dosages of Drugs in Emergencies-Reply
Authors: A. S. Kirshenbaum
Journal: JAMA (1987)

<h3>In Reply.—</h3> Byerly et al share my concern that the formula recommended by the American Heart Association for preparation of cardiac infusion drugs is problematic. The dosage range for isoproterenol, epinephrine, and norepinephrine is from 0.1 μg/kg/min to 1 μg/kg/min. Following the formula set forth by the AHA,<sup>1(p2967)</sup>0.6 times the body weight (in kilograms) equals the milligrams of drug added to the diluent to make 100 mL, to be infused at 1 mL/h. This amount delivers 0.1 μ/kg/min. It is inconceivable, however, that a drip rate of 1 mL/h will ever deliver any drug to the arrested or resuscitated patient, let alone visibly drip out of the intravenous tubing! Byerly et al are also correct in pointing out that the number of ampules needed to supply the dose of isoproterenol, epinephrine, or norepinephrine calculated using the AHA formulawould be unavailable in most settings. Byerly et al